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David H. MacLennan⁎, Elena Zvaritch
Banting and Best Department of Medical Research, University of Toronto, Charles H. Best Institute, 112 College St., Toronto, Ontario, Canada M5G 1L6We are grateful to Drs. Gronert, Tobin and Muldoon for pointing
out the fact that MH-type reactions have been induced in humans by
stress.Wewere aware of thework cited, but, in an effort to stress the
point that there is duality to the cause of MH reactions (a point
which is fully developed in other parts of the review), we stated “…
triggering of an MH reaction, … requires the presence of both a
causal mutation and either a triggering anesthetic, or, in the case of
pigs, stressful conditions.” Nevertheless, their commentary illumi-
nates an area to which we had not given appropriate attention or
clarity.
In our further comments, wewill attempt to clarify the issue raised.
Multiple ryanodine receptor isoforms are encoded by multiple genes,
RYR1, RYR2 and RYR3; and this is also the case for RyR1-interrelated
and -interacting muscle Ca2+ regulatory proteins, including, dihy-
dropyridine receptors, calsequestrin and Ca2+ pumps and exchangers.
Structure/function differences among RyR1, RyR2 and RyR3 proteins
within any species aremuch greater than the differences amongRyR1s
expressed in different species, such as humans and pigs, and this is also
the case for the interacting Ca2+ regulatory proteins. The potential for
expression of different mixes of a whole variety of Ca2+ regulatory
proteins (Michael Berridge [1] has aptly described them as a “Ca2+
signaling toolkit”) is what gives each muscle its special properties.
Over time, evolution, separating humans and pigs as unique species,
has altered the muscle milieu in which Ca2+ regulatory proteins
function, inevitably altering the precise manner in which their
signaling functions are regulated. Accordingly, it is always a great
relief to scientists toﬁnd that knockout or knockinmouse lines, or lines
over-expressing transgenes, display the characteristics of the human
disease, since this is often not the case.
In comparing RyR1-related diseases in pigs and humans, there are
apparent differences. For example the halothane challenge test failed to
identify heterozygous MH pigs, making it impossible to eliminate the
gene from breeding stock until the precise mutation was identiﬁed [2].
By contrast, thevastmajority of heterozygousMHhumansare identiﬁedDOI of original article: 10.1016/j.bbamcr.2010.11.009.
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doi:10.1016/j.bbamcr.2011.08.002by their own or a relative's reaction to anesthetics. On the other hand,
the reason to rid swine stocks of the MH mutant (HAL/RYR1) allele has
nothing to do with their halothane-sensitivity, but much to dowith the
fact that homozygousMHpigs are highly susceptible to stress and often
die before they reach the market — hence the name for the disorder is
not porcine MH but porcine stress syndrome (PSS).
The analog of the porcine MH mutation in the HAL/RYR1 gene
(R615C in pigs: R614C in humans) has been reported in about 82
unrelated human cases and/or families and has been found to be
homozygous in 5 cases [3–5]. There is also a report of a C35R
homozygote [6] and there are several reports of compound hetero-
zygotes for causative RYR1 mutations. Since presentation was
unremarkable in any of these reports, it can be inferred that these
patients were clinically normal. In one report [5], a homozygous
R614C woman was the mother of two children, suggesting robust
health. R163C is one of the most frequent MH mutations worldwide
and it has been studied in generations of patients, but case 2 described
by Drs. Gronert, Tobin and Muldoon is the only report of a possible
stress-induced death linked to this mutation. Even the presence of the
R163C mutation in their case study does not, in itself, prove
association of sudden death with an MH reaction.
Since it seems clear that the vast majority of heterozygous MH
humans are not particularly susceptible to stress-induced MH, the
cases cited by Drs. Gronert, Tobin and Muldoon tend to be the
exception rather than the rule for human MH. Indeed, in a recent
publication [7], one of the authors of the commentary described a 30-
year debate in which the central issue “– is the idea that some MH
susceptible patients may develop awake nonanesthesia-related
manifestations similar to that seen in porcine stress syndrome.” She
further wrote, “Although a link has never been established by
controlled clinical studies, individual case reports and a small number
of clinical series support an association between unexpected
exertional rhabdomyolysis and MH susceptibility, two syndromes
characterized by abnormal intracellular skeletal muscle calcium
regulation.”
The genetic basis of exertional rhabdomyolysis is an important
issue for the uniformed services and Dr. Muldoon, as well as Drs
Gronert, Tobin and others must be lauded for taking on the worthy
cause of developing “stress-induced MH” into a viable research area
within the MH ﬁeld [8]. However, any statement concerning anhts reserved.
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with the utmost caution since it could cause unnecessary and
unjustiﬁed alarm among MH patients.
Addendum:
Drs. Gerald Gronert, Joseph Tobin and Sheila Muldoon, are
prominent academic clinicians in the MH ﬁeld. As a component of our
response to their Letter to the Editor, they have here drawn up
guidelines for advice to MH patients, which we fully support, that
attempt to reconcile the fact thatmostMHpatientswill not experience a
stress-related episode, but a subset of rareMHSpatients is at higher risk.
Most MHS patients have no awake symptoms during adverse
conditions and need not limit environmental/stress situations. As with
the normal population, they'll sensibly adapt to adverse conditions. Rare
MHS patients, with a personal or family history of intolerance to heat or
other stress, shouldnot over-exert. If early symptomsbegin, they should
reduce stressful activity to minimize the likelihood of a stress-induced
MH episode. They should begin symptomatic treatment, particularly
cooling. Each patient must determine her/his own limits, and have
dantrolene capsules available.
But rhabdomyolysis looms; it may occur during MH and in other
conditions of skeletal muscle. Associated with anesthesia, it can be
explosive in release of potassium and myoglobin, with immediate
hyperkalemic cardiac arrest, and gradual evidence of renal failure. One
example sufﬁces: an 11 y/o girl arrested after receiving succinylcho-
line, with potassium >10 mEq/L, and creatine kinase 671,744 IU/L.
She required cardiac bypass perfusion with saline to restore
potassium to normal, hemodialysis, and she recovered fully. Contrac-
ture studies at UC Davis 20 months later ruled out MH [9].References
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